Funding · Healthcare & Life Sciences

4baseCare raises Rs 128 Cr in Series B round

By Startup Enthusiast · 11 June 2026

What they do

4baseCare provides AI-led genomic cancer diagnostics through its OncoTwin platform

The company closed a Series B round of Rs 128 Cr with growX Ventures leading the top-up

Funds support global expansion and lower pricing for underrepresented populations

4baseCare has closed its Series B funding round totaling Rs 128 Cr.
The total amount includes an earlier tranche of Rs 90 Cr and a top-up of Rs 38 Cr.
growX Ventures led the top-up investment round with participation from existing backers.
Infosys participated as a strategic innovation investor in this latest funding stage.
Co-lead investors for the initial Series B tranche were Ashish Kacholia and Lashit Sanghvi.
Existing backer Yali Capital also participated in the current funding round.
The company reported annual revenue of approximately Rs 40 Cr at the time of closing.
4baseCare aims to cross Rs 100 Cr in revenue within the next 12-18 months.

India sees around 15 lakh new cancer cases annually according to market context.
Approximately 70% of these cases are diagnosed at advanced stages in India.
The startup addresses the underrepresentation of non-Caucasian populations in genomic data globally.
Adoption is spreading from tier 1 cities to tier 2 and tier 3 locations.

4baseCare focuses on precision oncology and genomics-driven cancer diagnostics services.
Its core product is the OncoTwin platform which uses AI clinical decision support.
The platform analyzes multimodal datasets including genomic, pathology, radiology, and clinical data.
The company operates 4 active labs currently within India.
It performs approximately 1,500 genomic tests per month at present capacity.
Projected monthly test volume is expected to reach 8,000-10,000 tests soon.
The firm pursues a strategy of lower prices compared to competitors.
Some offerings cost nearly one-fourth of what competitor services charge.

Plans to expand lab network to Middle East, Southeast Asia, Latin America, and Central Asia.
Targeting entry into 8-10 additional countries over the next 12-18 months.
Forming partnerships with Max Healthcare, AIIMS Jammu, and Shankara Hospital for in-hospital labs.
Aiming to decentralize testing access across India through hospital integrations.

Product: Genomics-based cancer diagnostic tests and OncoTwin, an AI clinical decision support platform.
Customers: Oncologists, cancer patients, and hospital networks.
How it makes money: Fees for diagnostic testing services and software-driven clinical decision insights.
What sets it apart: Combines clinico-genomic and real-world lifestyle data tailored for underrepresented populations.
Operations: Operates genomics laboratories and partners with hospital networks across emerging markets.